The updates come after the Agency made the decision to limit the use of these agents as monotherapy in patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).
Half of meds ID'd in expanded access programs treat cancer; others for metabolic, endocrine diseases
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment.
Unapproved erectile dysfunction drugs are touted as a "healthy man alternative to the little blue pill."
NCCN recommended 47 FDA-approved drugs for 113 indications; 39% were extra recommendations
Trogarzo is given intravenously once every 14 days in combination with other antiretrovirals
Missouri-based Divinity Products Distribution will recall and destroy kratom-containing products
Agency advising doctors to consider prescribing other antibiotics to patients with coronary heart disease
Calls to poison centers regarding kratom increased 10-fold between 2010 and 2015
The FDA just approved a new short-acting insulin drug, Admelog, for patients with either T1D or T2D.
Semaglutide helps patients with diabetes reduce blood glucose levels and lower body weight.
Vabomere, which combines meropenem and vaborbactam, demonstrated superior efficacy to piperacillin/tazobactam.
The FDA is delaying implementation of last year's rules on cigars and electronic cigarettes currently on the market until 2021 and 2022, respectively.
The agency will now give priority reviews to new generic drugs until there are 3 on the market.
Amputations of the toe and middle of the foot were the most common, but leg amputations below and above the knee also occurred.
Company asks FDA to approve ferric citrate for iron deficiency anemia in patients with non-dialysis dependent chronic kidney disease.
Noctiva is taken 30 minutes before bed and is designed to increase absorption of water through the kidneys.
The drug is indicated for treating patients with locally advanced or metastatic disease that progresses despite platinum-containing chemotherapy.
After analyzing new data, the FDA again warns that the diabetes drug may be associated with an increased risk for bladder cancer.
Updated label for patiromer now recommends the drug be taken at least 3 hours before or after other oral medications.
The new FDA warning alerts prescribers to the abuse potential of testosterone.
Labeling changes will alert prescribers to the abuse potential of testosterone and the serious adverse effects.
Labeling information will include data showing the drug reduces the risk of radiographic progression versus bicalutamide.
While ADFs of opioids may help mitigate the risk of opioid abuse, they have limitations as well.
Once-daily injection to improve glycemic control, along with diet and exercise.
Fluoroquinolones such as Cipro, Levaquin should be reserved for life-threatening infections.
The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) is absorbed by the body after about 3 years.
Calcifediol formulation is indicated for CKD stage 3 or 4 patients with secondary hyperparathyroidism associated with vitamin D insufficiency.
The Food and Drug Administration (FDA) announced it is strengthening the current warning about the risk of acute kidney injury for drug products containing canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)